Schizophrenia & Psychosis — GCC Nursing Guide

▸ DSM-5 / ICD-11 Diagnostic Criteria

Core Criteria (DSM-5 A)

2 or more of the following, each present for a significant portion of ≥1 month (with ≥1 from items 1–3):

1. Delusions
2. Hallucinations
3. Disorganised speech
4. Grossly disorganised or catatonic behaviour
5. Negative symptoms

Duration & Functional Criteria

Criterion B: Social/occupational dysfunction
Criterion C: Duration ≥6 months (with ≥1 month active symptoms)
Criterion D: Exclude schizoaffective / mood disorder
Criterion E: Exclude substance / medical cause
Criterion F: No ASD history (or ASD present — add full criteria)

ICD-11: similar — requires ≥1 first-rank symptom OR ≥2 other symptoms; duration ≥1 month

▸ Positive Symptoms

Hallucinations — Types

Auditory (most common) Visual Olfactory Tactile Command (high risk)

Delusions — Types

Persecutory Reference Grandiose Nihilistic Passivity phenomena

Thought Disorder

Loosening of associations — tangential, illogical connections
Flight of ideas — rapid topic shifting
Thought insertion — thoughts placed by external force
Thought withdrawal — thoughts removed
Thought broadcasting — thoughts heard by others

▸ Negative Symptoms — AAAVVO

          AAlogia — poverty of speech, reduced output
          AAnhedonia — inability to experience pleasure
          AAvolition — lack of motivation, goal-directed activity
          VAffect flat (blunted affect) — diminished emotional expression
          VVocabulary reduced — limited speech content
          OOccupational dysfunction — impaired work/social role
        

Note: Negative symptoms are harder to treat than positive symptoms. Poor antipsychotic response. Associated with worse long-term prognosis.

▸ First Episode Psychosis (FEP) Workup

Exclude Organic Causes First

Drug-induced psychosis — cannabis, stimulants, steroids, anticholinergics
Delirium — acute onset, fluctuating consciousness, medical illness
Brain tumour / SOL — focal neuro signs, headache, raised ICP
Autoimmune encephalitis — anti-NMDAR, anti-LGI1: fever, seizures, movement disorder
Thyroid / metabolic — TFTs, LFTs, glucose, electrolytes
Temporal lobe epilepsy — EEG
Neurosyphilis / HIV — STI screen

FEP Investigations

FBC / CMP TFTs LFTs Glucose / HbA1c UDS (urine drug screen) MRI Brain EEG if indicated Anti-NMDAR Ab ECG (QTc baseline)

▸ Differential Diagnoses of Psychosis

Diagnosis	Key Feature	Duration	Differentiator
Schizophrenia	Positive + negative symptoms	≥6 months	No sustained mood episode
Schizophreniform	Same as schizophrenia	1–6 months	May recover fully
Brief psychotic disorder	Positive symptoms only	1 day–1 month	Sudden onset, often stress-related
Schizoaffective	Psychosis + mood episodes	Variable	Psychosis present independent of mood
Delusional disorder	Non-bizarre delusions only	≥1 month	No hallucinations / disorganisation
Bipolar I (psychotic)	Psychosis during mania	Episodic	Mood-congruent; mood episode prominent
Drug-induced	Psychosis after substance use	Resolves with abstinence	UDS positive; timeline correlation

Key Principle: First-generation antipsychotics (FGAs) have higher EPS risk. Second-generation (SGAs) have higher metabolic risk. Choose based on patient profile, symptom profile, and adherence history.

▸ First-Generation (Typical) Antipsychotics — FGAs

Drug	Route	Typical Dose	Key EPS Risk	Notes
Haloperidol	PO / IM / IV	2–20mg/day	High	Gold standard for acute agitation IM; high D2 affinity
Chlorpromazine	PO / IM	75–300mg/day	Moderate	Sedating; photosensitivity; orthostatic hypotension
Flupentixol	PO / depot	3–18mg/day	High	Also used in low-dose depression; depot available

▸ Extrapyramidal Side Effects (EPSE) — Types

Akathisia— restlessness, unable to sit still, pacing. Onset: days–weeks

Acute Dystonia— painful muscle spasm, eye deviation (oculogyric crisis), torticollis. Onset: hours–days. EMERGENCY

Drug-induced Parkinsonism— tremor, rigidity, bradykinesia. Onset: weeks–months

Tardive Dyskinesia— late involuntary oro-facial movements (tongue/lip smacking, choreiform limb movements). Onset: months–years. May be irreversible

EPS Management

Akathisia: Reduce dose / switch SGA, propranolol 10–40mg, mirtazapine
Acute Dystonia: IM procyclidine 5–10mg or benztropine — URGENT
Drug-induced Parkinsonism: Reduce dose, switch to SGA, procyclidine PO
Tardive Dyskinesia: Reduce / stop FGA, switch to clozapine or quetiapine; consider valbenazine/tetrabenazine

▸ Second-Generation (Atypical) Antipsychotics — SGAs

Drug	Dose Range	Metabolic Risk	EPS Risk	Key Points
Olanzapine	5–20mg/day	High	Low	Weight gain ++; sedation; DM risk; smoking alters levels
Risperidone	2–8mg/day	Moderate	Moderate	Hyperprolactinaemia ++; depot available; dose-dependent EPS
Quetiapine	150–750mg/day	Moderate	Very low	Sedating; good for sleep; used in bipolar; low EPS ideal for PD
Aripiprazole	10–30mg/day	Low	Low	Partial D2 agonist; activating; minimal weight gain; akathisia risk
Amisulpride	400–800mg/day	Low	Moderate	Selective D2/D3; good negative symptoms at low dose; prolactin rise
Clozapine	150–600mg/day	High	Lowest	Treatment-resistant only; agranulocytosis risk; mandatory monitoring

▸ Depot (Long-Acting Injectable) Antipsychotics

Depot	Frequency	Base Drug
Zuclopenthixol decanoate	Every 2–4 weeks	FGA
Flupentixol decanoate	Every 2–4 weeks	FGA
Paliperidone palmitate	Monthly / 3-monthly	SGA
Aripiprazole monohydrate	Monthly	SGA
Risperidone microspheres	Every 2 weeks	SGA

Depot Injection Technique Guide ▼

Site: Gluteus maximus (preferred) or vastus lateralis; avoid deltoid for oil-based
Needle: 21–23G, 2–3.5 inch for IM gluteal (BMI dependent)
Z-track technique: Pull skin/subcut tissue 2–3cm laterally before injection; hold during injection; release after withdrawal — reduces leakage into subcut tissue and pain
Aspiration: Not required per current evidence; observe for intravenous placement signs
Rotation: Alternate sites each visit; document injection site
Warm oil: Warm depot to room temperature before administration
Post-injection: Observe patient 30 min (PIPO syndrome risk with aripiprazole depot — post-injection delirium sedation syndrome)

PIPO Syndrome (Aripiprazole LAI): Rare but serious — accidental IV injection causes sedation, confusion, dysarthria within 1 hour. Observe all patients post-injection for minimum 3 hours (manufacturer advice).

▸ PRN Antipsychotics — Acute Agitation

NICE / GCC Protocol

De-escalation first: Verbal de-escalation, offer oral medication before IM

Oral PRN: Lorazepam 1–2mg PO or olanzapine velotabs 10mg PO
IM combination: Lorazepam 1–2mg IM + Haloperidol 5mg IM (standard)
IM alternative: Olanzapine 10mg IM (do NOT combine with IM lorazepam — respiratory depression risk)
Rapid tranquilisation: Monitor ECG (QTc), O2 sats, BP, respiratory rate q15min post IM
Resuscitation available: Flumazenil and airway equipment must be accessible

NEVER: Give IM olanzapine within 1 hour of IM benzodiazepine — risk of fatal respiratory arrest

Antipsychotic Side Effect Comparison ▼

Side Effect	Olanzapine	Risperidone	Quetiapine	Aripiprazole	Clozapine
Weight gain	+++	++	++	+/-	+++
Sedation	++	+	+++	+/-	+++
EPS	+	++	+/-	+	Lowest
Prolactin rise	+/-	+++	+/-	-	-
QTc prolongation	+	+	+	+/-	+
Hypotension	+	++	++	+/-	+++
Agranulocytosis	Rare	Rare	Rare	Rare	1–2%
Hypersalivation	-	-	-	-	+++

Clozapine requires mandatory haematological monitoring through a recognised monitoring service (CPMS). Dispensing is ONLY permitted if monitoring is up to date and WBC/ANC are within acceptable range.

▸ Clozapine Indications & Rationale

Treatment-resistant schizophrenia (TRS) — failed ≥2 adequate antipsychotic trials (different classes, adequate dose, adequate duration ≥6 weeks each)
Most effective antipsychotic for TRS — 30% additional responders
Reduces suicidality (FDA-approved for suicide risk in schizophrenia)
Reduces violence and rehospitalisation in TRS
Only antipsychotic that genuinely improves negative symptoms

Titration Schedule

Start: 12.5–25mg night 1–2 (inpatient preferred)
Week 1–2: Increase by 25–50mg every 1–2 days
Target range: 300–450mg/day in divided doses
Max: 900mg/day (rarely used)
Plasma level: 0.35–0.6 mg/L (trough) — therapeutic monitoring

▸ Clozapine Side Effect Management

Hypersalivation (sialorrhoea): Hyoscine hydrobromide patch 1.5mg/72h applied behind ear; pirenzepine; amisulpride low dose
Constipation / ileus: Encourage fluids, high-fibre diet; laxatives (lactulose/senna); macrogol (osmotic); monitor bowel movements daily — ileus is potentially fatal
Sedation: Take majority of dose at night; reduce dose if excessive
Hypotension: Slow titration; fludrocortisone; compression stockings
Nocturnal enuresis: Oxybutynin; restrict fluids at night
Weight gain / metabolic: Diet/exercise; metformin if DM develops; switch not possible in TRS

Clozapine Traffic Light Monitoring — WBC & ANC Thresholds ▼

GREEN — Continue clozapine
WBC ≥ 3.5 × 10⁹/L AND ANC ≥ 2.0 × 10⁹/L

AMBER — Increase monitoring (twice weekly)
WBC 3.0–3.5 × 10⁹/L OR ANC 1.5–2.0 × 10⁹/L
Continue clozapine — check twice weekly until back to green ×4 consecutive weeks

RED — STOP clozapine immediately
WBC < 3.0 × 10⁹/L OR ANC < 1.5 × 10⁹/L
Stop clozapine; urgent haematology referral; patient must NOT be rechallenged if neutrophil count fell below 0.5 (agranulocytosis)

Monitoring Frequency Schedule

Period	Frequency	Tests
Weeks 1–18	Weekly (highest agranulocytosis risk)	FBC including differential WBC
Weeks 19–52	Fortnightly	FBC including differential WBC
After 1 year	Monthly	FBC including differential WBC
Missed dose >48h	Re-titrate from start	FBC before restarting

▸ Agranulocytosis — Risk & Recognition

Cumulative incidence: 1–2%
Highest risk: Weeks 6–18 of treatment
Presentation: fever, sore throat, mouth ulcers, infections not resolving
Action: Stop clozapine, urgently check FBC, haematology review, consider G-CSF (filgrastim)
Risk factors: female sex, Asian ethnicity, initial neutrophil count lower

Absolute contraindication to rechallenge if confirmed agranulocytosis (ANC < 0.5 × 10⁹/L)

▸ Myocarditis & Seizure Risk

Myocarditis (Early Weeks)

Risk: 0.1–1%; typically weeks 1–4
Signs: chest pain, dyspnoea, fever, tachycardia, flu-like symptoms
Monitoring: Troponin I/T (baseline + weekly weeks 1–4); CRP; ECG
Action: stop clozapine, cardiac review, echocardiogram

Seizure Risk

Clozapine lowers seizure threshold — dose-dependent
Risk increases above 600mg/day and with rapid titration
Co-prescribe valproate (avoid carbamazepine — reduces WBC)
EEG if history of epilepsy before starting
Avoid fluvoxamine (raises clozapine levels significantly)

▸ Metabolic Monitoring Schedule — Clozapine

Parameter	Baseline	1 month	3 months	6 months	Annually
Weight / BMI	✓	✓	✓	✓	✓
Waist circumference	✓		✓		✓
Fasting glucose / HbA1c	✓		✓	✓	✓
Fasting lipids	✓		✓		✓
Blood pressure	✓	✓	✓	✓	✓
ECG (QTc)	✓				Annually
Troponin / CRP	✓	Wkly ×4
Clozapine plasma level			✓	✓	✓

▸ Therapeutic Alliance in Psychosis

Trust: Consistent, reliable presence; same nurse where possible; follow through on commitments
Non-judgmental stance: Do not challenge or argue about delusions directly; acknowledge distress
Consistency: Predictable routine; advance notice of changes; clear boundaries
Communication: Clear, simple, calm language; avoid over-stimulating environments
Engage family: With patient consent; psychoeducation for carers
Cultural sensitivity: Especially relevant in GCC — spiritual beliefs, family role

▸ Mental State Examination (MSE) in Schizophrenia

Appearance & Behaviour: Self-neglect, odd clothing, social withdrawal, thought blocking (pauses)
Speech: Poverty, neologisms, loosening of associations, tangentiality, circumstantiality
Mood: Blunted/flat affect; incongruent affect; anhedonia
Thought: Document form (disorder) + content (delusions — type, systematised?)
Perception: Hallucinations — modality, frequency, content; command hallucinations?
Cognition: Attention, concentration, working memory (often impaired)
Insight: Grade 0–3 (full insight → partial → none); crucial for concordance
Risk: Document clearly — self-harm, violence, safeguarding, exploitation

▸ Risk Assessment — Structured Approaches

HCR-20 — Violence Risk

H — Historical (10 items): Previous violence, young age at first violence, relationship instability, employment problems, substance use, mental illness, psychopathy, early maladjustment, personality disorder, prior supervision failure
C — Clinical (5 items): Lack of insight, negative attitudes, active symptoms, impulsivity, unresponsive to treatment
R — Risk Management (5 items): Plans lack feasibility, exposure to destabilisers, lack of personal support, non-compliance with remediation, stress

Command Hallucinations

High-risk features:
• Voices commanding self-harm or harm to others
• Patient believes voices are real and powerful
• Patient has complied with commands previously
• Identity of voice (powerful/known person)

Additional Risk Domains

Fire-setting: History, current ideation, access to means
Self-harm: Suicidal ideation, intent, plan, means, previous attempts
Safeguarding: Exploitation, cuckooing (property used by criminals), vulnerability to abuse

▸ Supported Decision-Making & Capacity

Presumption of capacity: All adults presumed to have capacity unless assessed otherwise
4-stage capacity test: Understand / Retain / Weigh up / Communicate decision
Supported decision-making: Provide information in accessible format; use interpreter; allow time; involve advocate (IMHA)
Best interests (if lacking capacity): MDT decision, least restrictive option, family involvement, document thoroughly
Mental Health Act: Involuntary admission — when risk to self/others AND refuses treatment
GCC note: Laws vary across GCC; family-centred decisions culturally important but patient rights must be upheld

▸ CBT for Psychosis (CBTp) Principles

Normalising model: Psychosis on a continuum with normal experience; reduce shame
ABC model: Activating event → Beliefs (about voice/delusion) → Consequences (emotional/behavioural)
Challenging catastrophic beliefs about voices rather than the voice content
Reality testing: Collaborative exploration of evidence for/against beliefs
Coping strategies: Distraction, activity scheduling, assertiveness with voices
Engagement is treatment: Even low-intensity CBTp reduces distress and hospitalisation

Recovery-Oriented Care Principles — CHIME Framework ▼

Connectedness
Peer support, social networks, relationships, belonging to community, family involvement

Hope
Belief in recovery, optimism about the future, motivation to change, positive expectations from others

Identity
Rebuilding positive sense of self beyond illness; overcoming stigma and internalised shame

Meaning
Meaningful roles, occupation, spirituality, quality of life. In GCC context: religion as a source of meaning and resilience

Empowerment
Personal responsibility, control over decisions, overcoming stigma, self-management, advocacy

Mortality gap: People with schizophrenia die 10–25 years earlier than the general population — largely preventable physical health causes (cardiovascular disease, metabolic syndrome, smoking-related disease). Physical health monitoring is a core nursing responsibility.

▸ Metabolic Syndrome Monitoring

Annual Monitoring (minimum)

Waist circumference: >94cm (male) / >80cm (female) = increased risk
Fasting glucose / HbA1c: DM (>7mmol/L fasting or HbA1c ≥48 mmol/mol)
Fasting lipids: Total cholesterol, LDL, HDL, triglycerides
Blood pressure: ≥130/85 mmHg = metabolic syndrome criterion
BMI: >30 = obese; weight gain monitoring monthly in first 3 months of antipsychotic

Metabolic Syndrome Criteria (IDF)

Central obesity PLUS ≥2 of: raised TG, low HDL, raised BP, raised fasting glucose

▸ Smoking & Antipsychotic Drug Interactions

60–90% of people with schizophrenia smoke — highest rate of any psychiatric diagnosis. Smoking induces CYP1A2 enzyme.

Smoking increases CYP1A2 activity → faster drug metabolism
Clozapine levels: Smokers need higher doses (40–50% reduction in plasma levels); if patient stops smoking levels RISE — monitor for toxicity
Olanzapine: Similar effect — doses may need adjusting if smoking status changes
NRT / varenicline: Safe to use with antipsychotics; monitor plasma levels if initiating smoking cessation
Bupropion: Caution with clozapine — lowers seizure threshold
Smoking cessation should be actively supported with monitoring of drug levels

▸ Diabetes Management with Antipsychotics

Olanzapine and clozapine associated with insulin resistance, DM, and diabetic ketoacidosis (DKA)
New-onset DM: Consider switching antipsychotic (if not clozapine-dependent); add metformin; involve diabetes team
HbA1c targets: 48–53 mmol/mol (standard); less strict if complex needs
Foot care: Annual diabetic foot assessment; neuropathy screening
DKA risk: High in early antipsychotic treatment — counsel patients on symptoms (polyuria, polydipsia, nausea)

▸ Sexual Health — Hyperprolactinaemia

Antipsychotic-Induced Hyperprolactinaemia

Most common with: risperidone, amisulpride, haloperidol
Consequences: amenorrhoea, galactorrhoea, reduced libido, erectile dysfunction, infertility
Long-term: reduced bone density (osteoporosis risk)
Monitoring: Prolactin level at baseline and if symptomatic
Management: Switch to aripiprazole (prolactin-sparing) or quetiapine; aripiprazole augmentation can lower prolactin
Sexual health screening: Annual STI screen; contraception advice (amenorrhoea ≠ infertility)

▸ Substance Use — Dual Diagnosis

Cannabis use: strongly associated with psychosis onset and relapse; increases dopamine dysregulation
Alcohol: high comorbidity; increases non-concordance and violence risk
Stimulants (cocaine, amphetamines): precipitate and exacerbate psychosis
Integrated treatment model: Treat both mental health and substance use simultaneously; sequential treatment is less effective
Motivational interviewing; harm reduction approach; avoid confrontation
In GCC: alcohol and illicit substance use may be concealed due to legal/religious consequences — non-judgmental approach critical

▸ Cardiovascular & COPD Risk

Cardiovascular Risk

10-year CVD risk elevated: sedentary lifestyle, smoking, metabolic syndrome, antipsychotic effects on lipids
QTc monitoring: antipsychotics that prolong QTc (amisulpride, haloperidol, IV droperidol) — risk of torsades de pointes
Annual CVD risk assessment (QRISK3)
Statin therapy as per lipid guidelines

COPD in Chronic Schizophrenia

High smoking rates → COPD, chronic bronchitis, lung cancer
Smoking + clozapine/olanzapine: if COPD exacerbation requires admission and smoking cessation, monitor drug levels closely
Annual spirometry for long-term smokers

▸ Cultural Context in GCC Psychiatry

GCC-specific pattern: Psychiatric illness may be attributed to spiritual causes — jinn possession, sihr (black magic), or evil eye (hasad). Religious/traditional healers (raqi, shaikh) are often the first port of call, leading to delayed psychiatric presentation with more severe illness at first contact.

Jinn possession / sihr: Patient and family may attribute symptoms to supernatural causes; do not dismiss — explore spiritual meaning while ensuring psychiatric treatment
Family-concealment pattern: Family may hide diagnosis to avoid social stigma, preventing treatment-seeking
Late presentation: First contact often in crisis — acute agitation, forensic involvement, severe self-neglect
Ruqyah (Islamic healing): Recitation of Quran for healing — culturally acceptable; not incompatible with psychiatric treatment
Family role: Core in GCC — family should be included in care planning (with consent); they are primary carers
Gender dynamics: Female patients may have limited autonomy; male family member may speak on behalf — ensure patient voice is heard

▸ Legal & Regulatory Framework — GCC

Involuntary Treatment Laws

UAE: Federal Law No. 28 of 2021 — Mental Health Law; DHA and DOH implement locally; involuntary admission requires 2 psychiatrist certificates + judicial oversight
Saudi Arabia: Mental Health Act 1993 (Royal Decree); updated provisions; SFDA regulates clozapine registry
Kuwait / Qatar / Bahrain / Oman: Varying legislation; generally requires 2 physicians + family involvement for involuntary treatment

Forensic Psychiatry — Criminal Responsibility

Gulf legal systems (Sharia-influenced): mental illness may reduce criminal responsibility (diminished responsibility)
Court-ordered psychiatric assessment; forensic units in UAE (Al Amal Hospital), Saudi Arabia (Jeddah / Riyadh)
Insanity defence varies; Islamic jurisprudence considers absence of aql (reason) in criminal liability

Clozapine Registry — GCC

UAE: Clozapine monitoring available through DHA/DOH approved pharmacies; CPMS equivalent registry operational
Saudi Arabia: SCFHS-regulated; monitoring service through approved psychiatric centres (National Guard, MOH hospitals)

▸ Ramadan Fasting — Psychiatric Nursing Considerations

Antipsychotic Absorption & Timing

Reduced oral intake during fasting hours may affect drug absorption and serum levels
Medications typically moved to Iftar (breaking fast) and Suhoor (pre-dawn meal)
Clozapine: Divide doses at Iftar + Suhoor; plasma level monitoring during Ramadan recommended
Olanzapine: Single night dose at Iftar reasonable in stable patients
Dehydration → concentrated plasma levels — monitor for toxicity

Metabolic Considerations

Dietary changes during Ramadan — high-calorie Iftar meals may worsen glucose/lipid parameters
Weight monitoring should continue; HbA1c test timing affected by Ramadan (post-Ramadan testing more representative)
Sleep disruption (common during Ramadan) can trigger relapse in psychosis
Smoking pattern changes (non-smoking during daylight) may transiently raise clozapine/olanzapine plasma levels
Nurse should proactively review medication timing with patient before Ramadan begins

▸ DHA / DOH / SCFHS Exam Prep — High-Yield Topics

Clozapine Monitoring

ANC threshold to stop: < 1.5
WBC threshold to stop: < 3.0
Highest risk period: weeks 6–18
Weekly monitoring for first 18 weeks
Agranulocytosis = ANC < 0.5
Myocarditis monitoring: Troponin + CRP weeks 1–4
Therapeutic plasma level: 0.35–0.6 mg/L

EPS Types & Management

Acute dystonia: IM procyclidine — URGENT
Akathisia: propranolol / reduce dose
Parkinsonism: procyclidine PO / switch SGA
Tardive dyskinesia: switch to clozapine / valbenazine
TD occurs after months–years of FGA use
FGA with highest EPS: haloperidol

MSE & Documentation

Insight: always document (Grade 0–3)
Command hallucinations = HIGH RISK
Risk of violence: use HCR-20
Negative symptoms = AAAVVO
CBTp = normalising model
Recovery = CHIME
FEP workup: exclude organic first

SCFHS Psychiatric Nursing Competencies

Conduct biopsychosocial assessment including cultural factors
Administer and monitor psychotropic medications safely
Conduct MSE and document in electronic health record
Apply de-escalation techniques and least restrictive interventions
Manage rapid tranquilisation per protocol
Provide psychoeducation to patient and family
Facilitate recovery-oriented and person-centred care

DHA Mental Health Nursing Standards

Documentation in conformity with DHA EMR standards
Patient rights — informed consent; least restrictive practice
Clozapine must only be dispensed with valid CPMS authorisation in DHA facilities
De-escalation training mandatory for all psychiatric nurses
Physical health monitoring documented as part of care plan
Cultural competence in assessment — interpreter services where required

Schizophrenia & Psychosis GCC Nursing GuideDHA/SCFHS Exam Ready